Proteases and their inhibitors in human brain tumours: A review

Anticancer Research

Volumn 17, Issue 6 B, 1997, Pages 4151-4162

  Rooprai, Harcharan K ^a   McCormick, Derek ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Brain tumours; Cysteine proteinases; Extracellular matrix; Matrix metalloproteinases; Proteases; Serine proteinases

Indexed keywords

CATHEPSIN B; CATHEPSIN L; CYSTEINE PROTEINASE; GELATINASE; MATRIX METALLOPROTEINASE; PROTEINASE; PROTEINASE INHIBITOR; SERINE PROTEINASE; UROKINASE; UROKINASE RECEPTOR;

BASEMENT MEMBRANE; BRAIN TUMOR; CANCER INVASION; EXTRACELLULAR MATRIX; GLIOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

BRAIN NEOPLASMS; CELL MOVEMENT; CYSTEINE ENDOPEPTIDASES; ENDOPEPTIDASES; EXTRACELLULAR MATRIX; HUMANS; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; PROTEASE INHIBITORS; SERINE ENDOPEPTIDASES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0031443035     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Rutka JT, Apodaca G, Stern R and Rosenblum M: The extracellular matrix of the central nervous and peripheral nervous system: Structure and function. J Neurosurg 69: 155-170, 1988.
2. Liotta LA: Tumour invasion and metastases - role of the extracellular matrix: Rhodes Memorial Award Lecture. Cancer Res 46: 1-7, 1986.
3. Matrisian LM: The matrix-degrading metalloproteinases. Bioessays 14: 455463, 1992.
4. Mignatti P and Rifkin DB: Biology and biochemistry of proteinases in tumour invasion. Physiol Rev 73: 161-195, 1993.
5. Mareel MM, De Baetselier P and Van Roy FM: Cellular activities implicated in invasion and metastasis. In: Mechanisms of invasion and metastasis, MM Mareel, P De Baetselier and FM Van Roy (eds) pp 73-219 (RC, Press, Boca Raton), 1991.
6. Werb Z: Proteinases and matrix degradation. In WN Kelley, Ruddy S, Sledge CB (ed). Textbook of Rheumatology. WB Saunders, Philadelphia, pp-300-32 1, 1989.
7. Arnavoorian S, Murphy AN, Stetler-Stevenson WG and Liotta LA: Molecular aspects of tumour cell invasion and metastasis. Cancer 71: 1368-1383, 1993.
8. Khokha R and Denhardt DT: Matrix metalloproteinases and tissue inhibitor of metalloproteinases: A review of their role in tumorigenesis and tissue invasion. Invasion and Metastasis 9: 391-405, 1989.
9. Emonard H and Grimaud JA: Matrix metalloproteinaces: A review. Cell Mol Biol 36: 131-153, 1990.
10. Matrisian M. Metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: 2145-2153, 1990.
11. Docherty AJP and Murphy G: The tissue metalloproteinase family and the inhibitor TTMP: a study using cDNAs and recombinant proteins. Ann Rheum Dis 49: 469-479, 1990.
12. Birkedal-Hansen H, Werb Z, Welgus HG, Van Wart HE: Eds, Matrix metalloproteinases and inhibitors. Matrix Spec Suppl 1: Gustav Fischer, Stuttgart, 1992.
13. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkendel-Hansen B, DeCarlo A and Engler JA: Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 4: 197-250, 1993.
14. Ennis BW and Matrisian LM: Matrix degrading metalloproteinases. J Neuroncol 18: 105-109, 1994.
15. Romanic AM and Madri JA: Extracellular-matrix-degrading proteinases in the nervous system. Brain Pathol 4: 145-156, 1994.
16. Tryggvason K, Hoyhtya M and Salo T: Proteolytic degradation of extracellular matrix in tumour invasion. Biochim Biophys Acta 907: 191-217, 1987.
17. Himelstein BP, Canete-Soler R, Bernhard EJ, DiLlcs DW and Muschel RJ: Metalloproteinases in tumour progression: The contribution of MMP-9. Invasion and Metastasis 14: 246-258, 1994.
18. McDougall JR and Matrisian LM: Contribution of tumour and stromal matrix metalloproteinases to tumour progression, invasion and metastasis. Cancer and Metastasis Review 14: 351-362, 1995.
19. Brown PD and Giavazzi R: Matrix metalloproteinase inhibition: A review of antitumour activity. Annals of Oncol 6: 967-974, 1995.
20. Woessner JF Jr: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: 2145-2154, 1991.
21. Docherty AJP, O'C̃nnell J, Crabbe T, Angal S and Murphy G: The matrix metalloproteinase and their inhibitors: prospects for treating degenerative tissue diseases. TIBTECH 10: 200-207, 1992.
22. Gross J and Lapiere CM: Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 54: 1197-1204, 1962.
23. Freije JMP, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolovia J and Lopez-Otin C: Molecular cloning and expression of collagenase-3, a novel matrix metalloproteinase produced by breast carcinoma. J Biol Chem 269: 16766-16773, 1994.
24. Cawston TE and Billington C: Metalloproteinases in the rheumatic diseases. J Pathol 180: 115-117, 1996.
25. Okada Y, Nagase H and Harris EDJr: A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem 267: 14245-14255, 1986.
26. Nagase H, Barrett AJ and Wessner JF Jr: Nomenclature and glossary of the matrix metalloproteinases. Matrix Suppl 1: 421-424, 1992.
27. Welgus HG, Jeffrey JJ, Stricklin GP, Roswit WT and Eisen AZ: Characteristics of the action of human skin fibroblast collagenase on fibrillar collagen. J Biol Chem 255: 6806-6813, 1980.
28. Liotta LA, Tryggvason K, Garbisa S, Robey PG and Abe S: Partial purification and characterization of a neutral protease which cleaves type IV collagen. Biochem 20: 100-104, 1981.
29. Aimes RT and Quigley: Matrix metalloproteinase-2 is an interstitial collagenase. J Biol Chem 270: 5872-5876, 1995.
30. Bejarano PA, Noelken ME, Suzuki K, Hudson BG and Nagase H: Degradation of basement membranes by human matrix metalloproteinase 3 (stromelysin). Biochem J 256: 413-419, 1988.
31. Miyazaki K, Hattori Y, Umenishi F, Yasumitsu H and Umeda M: Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line. Cancer Res 50: 7758-7764, 1990.
32. Murphy G, Cockett MI, Stephens PE, Smith BJ and Docherty AJP: Stromelysin is an activator of procolllagenase. A study with natural and recombinant enzymes. Biochem J 248: 265-268, 1987.
33. He C, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ and Goldberg GI: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 86: 2632-2636, 1989.
34. Suzuki K, Enghild JJ, Morodomi T, Salvesen G and Nagase H: Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochem 29: 10261-10270, 1990.
35. Miyazaki K, Umenishi F, Funahashi K, koshikawa N, Yasumitsu H and Umeda M: Activation of TIMP-2/progelatinase A complex by stromelysin. Biochem Biophys Res Commun 185: 852-859, 1992.
36. Ogata Y, Enghild JJ and Nagase H: Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267: 3581-3584, 1992.
37. Shapiro SD, Kobayashi DK and Ley TJ: Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem 268: 23824-23829, 1993.
38. Murphy G, Cockett MI, Ward RV and Docherty AJP: Matrix metalloproteinase degradation of elastin, type IV collagen, and proteoglycan A quantative comparison of the 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 277: 277-279, 1991.
39. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD. Goldberg GI and Welgus HG. Human 92-and 72-kilodaltaql type IV collagenases are elastases. J Biol Chem 266: 7870-7875, 1991.
40. Sato H, Okada Y, Cao J, Shinagawa A, Yamamoto E and Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370: 6165, 1994.
41. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, Kronberger A, He C, Bauer EE and Goldberg GI: H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 265: 6579-6587, 1988.
42. Kjeldsen L, Bjerrum OW, Johnson HD, Sehested M and Borregaard N: Human neutrophil gelatinase: a marker for circulating blood neutrophils. Purification and quantification by enzyme linked immunosorbent assay. Eur J Haematol 49: 180-191, 1992.
43. Kleiner DE, Tuuttila A, Tryggvason K and Stetler-Stevenson WG: Stabililty analysis of 72 kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochem 32: 1583-1592, 1993.
44. Salo T, Lyons JG, Rahemtulla F, Birkedal-Hansen H and Larjava H: Transforming growth factor B1 upregulates type IV collagenase in cultured human keratinocytes. J Biol Chem 226: 11436-11441, 1991.
45. Overall CM, Wrana JL and Sodek J. Transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor ß1 in human fibroblasts. J Cell Biol 226: 14064-14071, 1991.
46. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT and Liotta LA: tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA expression in tumour cell lines and human tumor tissues. J Biol Chem 265: 13933-13938, 1990.
47. Matrisian LM, Gliachenhaus N, Gesnel M-C and Breathnach R Epidermal growth factor and oncogenes induce transcription of the same cellular mRNA in rat fibroblasts. EMBO J 4: 1435-1440, 1985.
48. Kerr LD, Olashaw NE and Matrrisian LM: Transforming growth factor ß1 and cAMP inhibit transcription of epidermal growth factor-and oncogene-induced transin RNA. J Biol Chem 263: 16999-17005, 1988.
49. Okada Y, Morodomi T, Enghild JJ, Suzuki K, Yasui A, Nakanishi L Salvesen G and Nagase H. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblast: purification and activation of the precursor and enzymic properties. Eur J Biochem 194: 72 1-730, 1990.
50. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA and Goldberg GI: Mechanisms of cell surface activation of 72-kDa type IV collagenase. J Biol Chem 270: 1-8, 1995.
51. Murphy G and Docherty AJP: The matrix metalloproteinases and their inhibitor. Am J Respir Cell Mol Biol 7: 120-125, 1992.
52. Cawston TE: Tnhibitors of metalloproteinases. In: Barret AJ, Salveson G (eds) Proteinase inhibitors. Elsevier, Amsterdam, pp 589-610, 1986.
53. Welgus HG, Campbell EJ, Bar-Shavitz, Senior RM and Teitelbaum SL: Human alveolar macrophages produce a fibroblast-like collagenase and collagenase inhibitor. J Clin Invest 76: 219-224, 1985.
54. Stetler-Stevenson WG, Krutzsch HC and Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase family. J Biol Chem 264: 17374-17378, 1989.
55. Pavloff N, Staskus PW, Kishnani NS and Hawkes SP: A new inhibitor of metalloproteinases from chicken: ChlMP-3. A third member of the TIMP family. J Biol Chem 267: 1732 1-17326, 1992.
56. Apte SS, Bjorn RO and Murphy G: The gene structure of tissue inhibitor of metalloproteinases (IIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 270: 14313-14318, 1995.
57. Apodaca G, Rutka JT, Bouhana K, Berens ME, Giblin JR, Rosenblum ML, McKerrow JH and Banda MJ: Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 50: 2322-2329, 1990.
58. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
59. Cottam DW and Rees RC: Regulation of matrix metalloproteinases: Their role in tumour invasion and metastasis. Int J Oncol 2: 861-872, 1993.
60. Waxman J and Wasan H: The architecture of cancer: The tissue metalloproteinases and their inhibitors. Br Med J 305: 1306-1307, 1992.
61. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
62. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, Pontes JE, Crissman JC and Freidman R: High levels of tissue inhibitors of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56: 1654-1659, 1996.
63. Fassina G, Paglialunga G, Fontanini G, Cosimi A, Perrotta A, Aluigi MG, Ardizzoni A and Albini A: Expression of mRNA for gelatinase A and TIMP-2 in cell cultures and tissue samples derived from breast and lung carcinomas. Int J Oncol 8: 253-261, 1996.
64. Woessner JF Jr: Quantification of matrix metalloproteinases in tissue samples. In Methods in Enzymology 248: 510-528, 1995.
65. Halaka AN, Blmning RAN, Bird CC, Gibson M and Reynolds JJ: Production of collagenase and inhibitor (TIMP) by intracranial tumours and dura in vitro. J Neurosurg 59: 461-466, 1983.
66. Paganetti PA, Caroni P and Schwab ME: Glioblastoma infiltration into central nervous system tissue in vitro: involvement of a metalloproteinase. J Cell Biol 707: 2281-2291, 1988.
67. Rutka JT, Giblin JR, Apodaca G, DeArmond SJ Stern R and Rosenblum ML: Inhibition of growth and induction of differentiation in a malignant glioma cell line by normal leptomeningeal extracellular matrix proteins. Cancer Res: 47: 3515-3522, 1987.
68. Colton CA, Keri JE, Chen W-T and Monsky WL: Protease production by cultured microglia: Substrate gel analysis and immobalized matrix degradation. J Neurosci Res 35: 297-304, 1993.
69. Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T and Okada Y: Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases-1 by human brain tumors. J Neurosurg 81: 69-77, 1994.
70. Rao JS, Steck PA, Mohanam S, Stetler-Stevenson WG, Liotta LA and Sawaya R: Elevated levels of Mr 92,000 type IV collagenase in human brain tumours. Cancer Res 55: 2208-2211, 1993.
71. Rao JS, Steck PA, Tofilon P, Boyd D, Ali-Osmon F, Stetler-Stevenson WG, Liotta LA and Sawaya R: Role of plasminogen activator and 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. J Neuro-Oncol 18: 129-138, 1994.
72. Rao JS, Yamamoto M, Mohanam S, Gokaslan ZL, Fuller GN, Stetler-Stevenson WG, Rao VH, Liotta LA, Nicolson GL and Sawaya RB: Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP9) in human gliomas. Clin Exp Metastasis 14: 12-18, 1996.
73. Sawaya RE, Yamamoto M, Gokasalan ZL, Wang SW, Mohanam S, Fuller GN, McCutcheon E, Stetler-Stevenson WG, Nicholson GL and Rao JS: Expression and localization of 72-kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis 14: 35-42, 1996.
74. Yamamoto M, Mohanam S, Sawaya R, Fuller GN, Sciki M, Sato H, Gokaslan ZL, Liotta LA, Nicolson GL and Rao JS: Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumours in vivo and in vitro. Cancer Res 56: 384-392, 1996.
75. Nakano A, Tani E, Miyazaki K, Furuyama J and Matsumoto T: Expression of matrilysin and stromelysin in human glioma cells. Biochem Biophys Res Commun 192: 999-1003, 1993.
76. Merzak A, McCrea S, Koocheckpour S and Pilkington GJ: Control of human glioma cell growth, migration, and invasion in vitro by transforming growth factor-ß1. Br J Cancer. 70: 199-203, 1994.
77. Mohanam S, Wang SW, Rayford A, Yamamoto M, Sawaya R, Nakajima M, Liotta LA, Nicolson GL, Stetler-Stevenson WG and Rao JS: Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis 13: 57-62, 1995.
78. Merzak A, Parker C, Koochekpour S, Sherbert GV and Pilkington GJ: Overexpression of the 18A/mts1 gene and down-regulation of the TIMP-2 gene in invasive human glioma cell lines in vitro. Neuropath Appl Neurobiol 20: 614-619, 1994.
79. Rutka JT, Matsuzawa K, Hubbard SL, Fukuyama K, Becker LL, Stetler-Stevenson W, Edwards DR and Dirks PB: Expression of TIMP-1, TIMP-2, 72-and 92-kDa type IV collagenase transcripts in human astrocytoma cell lines: Correlation with astrocytoma cell invasiveness. Int J Oncol 6: 877-884, 1995.
80. Matsuzawa K, Fukuyama K, Hubbard SL, Dirks PB and Rutka IT: Transfection of an invasive human astrcytoma cell line with a TIMP-1 cDNA: Modulation of astrocytoma invasive potential. J Neuropath Expt Neurobiol 55: 88-96, 1996.
81. Nakano A, Tani E, Miyazaki K, Yamamoto Y and Puruyama J-I: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 83: 298-307, 1995.
82. Maidment SL, Merzak A, Koochekpour S, Rooprai HK, Rucklidge GJ and Pilkington GJ: The effect of exogenous gangliosides on metalloproteinase secretion by human glioma cells in vitro. E J Cancer, 32: 868-871, 1996.
83. Rossi M, Rooprai HK, Maidment SL, Rucklidge GJ and Pilkington GJ: The influence of sequential, in vitro passage on secretion of matrix metalloproteinases by human brain tumour cells. Anticancer Res 16: 121-128, 1996.
84. Seftor REB, Seftor EA, Grimes WJ, Liotta LA, Stetler-Stevenson WG, Welch DR and Hendrix MJC: Human melanoma cell invasion is inhibited in vivo by swainsonine and deoxymannojirimycin with a concomitant decrease in collagenase IV expression. Melanoma Res 1: 43-54, 1991.
85. Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'shea M and Docherty AJ: The N-terminal domain of tissue inhibitors of metalloproteinase retains metalloproteinase inhibitory activity. Biochem 30: 8079-8101, 1991.
86. Nakagawa T, Kuboh T, Kabuto M and Kodera T: Captopril inhibits glioma cell invasion in vitro: Involvement of matrix metalloproteinases. Anticancer Res 75: 1985-1990, 1995.
87. Buck MR, Karustis DG, Day NA, Honn KV and Sloane BF. Degradation of extracellular matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 282: 273-278, 1992.
88. Lah TT, Buck MR, Honn KV, Crissman JD, Rao NC, Liotta LA and Sloane BF. Degradation of laminin by human tumor cathespin B. Clin Exp Metastasis 7: 461468, 1989.
89. Recklies AD and Poole AR. Proteolytic mechanisms of tissue destruction in tumor growth and metastasis. In Liver Metastasis (Weiss L and Gilbert R eds) Boston, Hall, 1982, pp 77-95.
90. Eeckhout Y and Vaes G. Purther studies on the activation of procollagenase, the latent precursor of bone collagenase. Spontaneous activation. Biochem J 166: 21-31, 1977.
91. Kobayashi H, Ohi H, Sugimura M, Shinohara H. Pujii T and Terao T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 52: 3610-3614, 1992.
92. Keppler D, Abrahamson, M and Sordat B: Secretion of cathepsin B and tumour invasion. Biochem Soc Trans 22: 4449, 1994.
93. Sloane BF and Honn KV: Cysteine proteinase and metastasis. Cancer Met Rev 3: 245-263, 1984.
94. Jessup JM. Cathepsin B and other proteases in human colorectal carcinoma. Am J Path 145: 253-262, 1994.
95. McCormick D. Secretion of cathepsin B by human gliomas in vitro. Neuropath Appl Neurobiol 19: 146-151, 1993.
96. Mikkelsen T, Yan P-S, Ho K-L, Sameni M, Sloane BF and Rosenblum ML. Immun localization of cathepsin B in human glioma: implications for tumour invasion and angiogenesis. J Neurosurg 83: 285-290, 1995.
97. Rempel SA, Rosenblum ML, Mikkelsen T, Van P-S, Ellis KD, Golembieski WA, Sameni M, Rozhin J, Ziegler G and Sloane BF. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 54: 6027-6031, 1994.
98. Sivaparvathi M, Sawaya R, Wang SW. Ravford A, Yamamoto M, Liotta L, Nicolson GL and Rao JS. Overexpression and localization of cathepsin B during the progression of human gliomas. Clin Exp Metastasis 13: 49-56, 1995.
99. Sivaparvathi M, Yamamoto M, Nicolson GL, Gokaslan ZL, Fuller GN, Liotta LA, Sawaya RA and Rao JS. Expression and immunohistochemical localisation of Cathepsin L during the progression of human gliomas. Clin Exp Metastasis 14: 27-34, 1996.
100. Walker B, Cullen BM, Kay G, Halliday IM, McGinty A and Nelson J. The synthesis, kinetic characterisation and application of a novel biotinylated affinity label for cathepsin B. Biochem J 283: 449-453, 1992.
101. Bromme D, Smith RA, Coles PJ, Kirschke H, Storer AC and Krantz A. Potent inactivation of cathepsins S and L by peptidyl (acyloxy)methyl ketones. Biol Chem Hoppe-Seyler 375: 343-347, 1994.
102. Shi G-P, Webb AC, Poster KE, Knoll JHM, Lemere CA, Munger JS and Chapman HA. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem 269: 1153-11536, 1994.
103. Wiederanders B, Bromme D, Kirschke H, Figura K, Schmidt B and Peters C. Phylogenetic conservation of cysteine proteinases. Cloning and expression of a cDNA coding for human cathepsin S. J Biol Chem 267: 13708-13713, 1992.
104. Bromme D, Bonneau PR, Lachance P, Wideranders B, Kirschke H, Peters C, Thomas DY, Storer AC and Vernet T. Functional expression of human cathepsin S in Saccharomyces cerevisae. Purification and characterization of the recombinant enzyme. J Biol Chem 268: 4832-4838, 1993.
105. Petanceska S, Burke S, Watson SJ and Devi L. Differential distribution of messenger RNAs for cathepsins B, L and S in adult rat brain: an in situ hybridization study. Neuroscience 59: 729-738, 1994.
106. Lemere CA, Munger JS, Shi G-P, Natkin L, Haass C, Chapman HA and Selkoe DJ. The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's Disease and Down Syndrome brain. An immunocytochemical study. Am J Pathol 146: 848-860, 1995.
107. Conese M and Blasi F. The urokinase/urokinase-receptor system and cancer invasion. Bailliers's Clin Haem 8: 365-389, 1995.
108. Romanic AM and Madri JA. Extracellular matrix-degrading proteinases in the nervous system. Brain Path 4: 145-156, 1994.
109. Estreicher A, Wohlwend A, Belin D, Schleuning W-D and Vassalli JD. Upregulation of uroldnase receptor expression on migrating endothelial cells. J Biol Chem 264: 1180-1189, 1989.
110. Dano K, Dabelsteen E, Nielson LS, Kaltoft K, Wilson EI and Zeuthen J. Plasminogen activating enzyme in cultured glioblastoma cells. J Histochem Cytochem 30: 1165-1170, 1982.
111. Reith A and Rucklidge GJ. Invasion of brain tissue by primary glioma: evidence for the involvement of urokinase-type plasminogen activator as an activator of type IV collagenase. Biochem Biophys Res Comm 186: 348-354, 1992.
112. Caccamo DV, Keohane ME and McKeever PE, Plasminogen activators and inhibitors in gliomas: an immunohistochemical study. Modern Path 7: 99-104, 1994.
113. Kinder DH, Berger MS, Mueller BA and Silber JA. Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain. Oncology Res 5: 409-414, 1993.
114. Yamamoto M, Sawaya R, Mohanam S, Bindal AK, Bruner JM, Oka K, Rao VH, Tomonaga M, Nicolson GL and Rao JS. Expression and localization of urokinasetype plasminogen activator in human astrocytomas in vivo. Cancer Res 54: 3656-3661, 1994.
115. Hsu DW, Efird JT and Hedley-White ET. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 147: 114-123, 1995.
116. Yamamoto M, Sawaya R, Mohanam S, Rao VH, Bruner JM, Nicholson GL and Rao JS. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 54: 5016-5020, 1994.
117. Gladson GL, Pijuan-Thompson V, Olman MA, Gillespie GY and Yacoub IZ. Upregulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol 146: 1150-1160, 1995.
118. Salonen E-M, Vaheri J, Pollanen R, Stephens P, Andreases M, Mayer K, Dano J, Gailit J and Ruoshlahti E. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 264: 6339-6343, 1989.
119. Mohanam S, Sawaya R, McCutcheon I, Ali-Osman P, Boyd D and Rao JS. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res 53: 4143-4147, 1993.
120. Moriyama T, Kataoka H, Tsubouchi H and Koono M. Concomitant expression of hepatocyte growth factor (HGF), HGF activator and c-met genes in human glioma cells in vitro. FEBS Lett 372: 78-82, 1995.
121. Silver LA, Murrills RJ and Etherington DJ. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res 1 75: 266-276, 1988.
122. Plow EF and Miles LA. Plasminogen receptors in the mediation of pericellular proteolysis. Cell Diff Dev 32: 293-298, 1990.
123. Blasi F, Vassalli J-D, and Dano K. Urokinase-type plasminogen activator: Proenzyme, receptor and inhibitors. J Cell Biol 104: 801-804, 1987.
124. Landau BJ, Kwaan HC, Verrusion EN and Brem SS. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumours. Cancer Res 54: 1105-1108, 1994.